CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Enzastaurin +1 moredrug
Likely dose
Enzastaurin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00414960
NCT00414960Phase 2Completed
CompareCT.gov

Phase IIB Randomized, Placebo-Controlled, Double-Blind Study of Enzastaurin HCL (LY317615) for Lung Cancer Prevention in Former Smokers

Eli Lilly and Company·interventional·Posted Dec 22, 2006·Updated Sep 21, 2020

In Brief

A Phase 2 clinical trial evaluating Enzastaurin and Placebo for Lung Cancer. Completed, enrolled 40 participants across 1 site.

Detailed Summary

To compare the difference of a marker of cellular proliferation in all bronchial biopsy specimens of former smokers stratified by lung cancer risk, collected before and after treatment per patient between the enzastaurin and placebo groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 22, 2006
Enrollment StartDec 1, 2007
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.5 years ago

Interventions

Enzastaurindrug

500 mg po QD for 6 months

Placebodrug

po QD for 6 months